BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 37311434)

  • 21. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
    Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
    Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular genetics of MDS/MPN overlap syndromes.
    Hunter AM; Padron E
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The International Consensus Classification of myelodysplastic syndromes and related entities.
    Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
    Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
    Maierhofer A; Mehta N; Chisholm RA; Hutter S; Baer C; Nadarajah N; Pohlkamp C; Thompson ER; James PA; Kern W; Haferlach C; Meggendorfer M; Haferlach T; Blombery P
    Blood Adv; 2023 Dec; 7(23):7346-7357. PubMed ID: 37874914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia.
    Schwartz JR; Walsh MP; Ma J; Lamprecht T; Wang S; Wu G; Raimondi S; Triplett BM; Klco JM
    Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 29891567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
    Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
    Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.
    Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2021 Aug; 16(4):336-344. PubMed ID: 34028637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions.
    Cobaleda C; Godley LA; Nichols KE; Wlodarski MW; Sanchez-Garcia I
    Cancer Discov; 2024 Mar; 14(3):396-405. PubMed ID: 38426560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7.
    Yoshida M; Tanase-Nakao K; Shima H; Shirai R; Yoshida K; Osumi T; Deguchi T; Mori M; Arakawa Y; Takagi M; Miyamura T; Sakaguchi K; Toyoda H; Ishida H; Sakata N; Imamura T; Kawahara Y; Morimoto A; Koike T; Yagasaki H; Ito S; Tomizawa D; Kiyokawa N; Narumi S; Kato M
    Br J Haematol; 2020 Dec; 191(5):835-843. PubMed ID: 32770553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytogenetics in the management of hematologic neoplasms with germline predisposition: guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
    Gachard N; Lafage-Pochitaloff M; Quessada J; Auger N; Collonge-Rame MA
    Curr Res Transl Med; 2023; 71(4):103416. PubMed ID: 37865978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
    Ng AP; Adams R; Tiong IS; Seymour L; Talaulikar D; Palfreyman E; Enjeti A; Tate C
    Pathology; 2024 Jun; 56(4):459-467. PubMed ID: 38580613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
    Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD
    Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genetic predisposition to myelodysplastic syndrome/leukemia].
    Hirabayashi S
    Rinsho Ketsueki; 2021; 62(8):1029-1037. PubMed ID: 34497189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
    Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline Predisposition to Hematolymphoid Neoplasia.
    Weinberg OK; Kuo F; Calvo KR
    Am J Clin Pathol; 2019 Aug; 152(3):258-276. PubMed ID: 31309983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
    Hughes CFM; Gallipoli P; Agarwal R
    Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.